Purpose of Review <p>This systematic review examined the available evidence on fracture risk in people with type 2 diabetes (T2D) using cardiovascular outcome trials with glucagon-like peptide-1 receptor agonist (GLP-1RA).</p> Recent Findings <p>A systematic Literature search identified 797 records, of which 643 remained after duplicate removal. Following screening, 20 studies met the criteria for inclusion.</p> Summary <p>Although GLP-1 RAs have demonstrated well-established benefits in glycaemic control, weight reduction, and cardiovascular protection, their impact on bone health remains incompletely understood. Preclinical studies suggest potential bone-protective effects, including increased bone mass, improved microarchitecture, and reduced bone resorption. However, evidence from human studies has been inconsistent. While some findings indicate a possible reduction in fracture risk with long-term GLP-1 RA therapy, further research is needed to clarify their role in bone metabolism and fracture prevention among people with T2D, particularly within the context of cardiovascular outcome trials.</p>